Top News

Ligand Buys IP From AstraZeneca

San Diego-based biopharmaceuticals firm Ligand Pharmaceuticals said today that it has purchased certain intellectual property and royalties from AstraZeneca's subsidiary, MedImmune. According to Ligand, it paid $2.75M for the IP and interest in future milestones and royalties for MEDI-528, an IL-9 antibody program being developed by MedImmune. The compound has possible applications in treating asthma.





Latest Headlines

Browse Issues


Keep up with all of the latest Southern California high tech news via email (it's free!)

or Cancel